Skip to main content
. 2019 Mar 8;49(4):271–280. doi: 10.1159/000499111

Fig. 2.

Fig. 2

The mean (SE) blood Hb concentrations at visits up to week 52 and at end of treatment using observed case data in (a) DIALOGUE 3 and (b) DIALOGUE 5. In DIALOGUE 3, for patients entering the main phase directly, baseline Hb was based on the average of scheduled Hb values from the last 4 visits in the parent study (evaluation period); for patients entering the main phase from the Hb-stabilization phase, baseline was defined as the average blood Hb concentrations of the last 2 visits of the Hb-stabilization phase. In DIALOGUE 5, the baseline Hb value was based on the average of scheduled Hb values from the last 4 visits of the parent study (the evaluation period). EOT, end-of-treatment; Hb, hemoglobin.